Close Menu

NEW YORK (GenomeWeb) – Invitae has commenced an underwritten public offering of $40 million worth of shares of its common stock, the company said yesterday.

All shares of common stock are offered by Invitae before deducting underwriting discounts, commissions or other expenses. JP Morgan Securities is the book-running manager for the offering.

Invitae said it will offer the underwriter a 30-day option to buy an as much as $6 million of shares of its common stock at the public offering price, less underwriting discounts and commissions.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jun
13

Ribosomal ribonucleic acid (rRNA) accounts for up to 99 percent of the total RNA depending on the cell type. 

Jun
18
Sponsored by
ArcherDX

This webinar will discuss background and clinical genomics of NTRK fusion detection in cancer. NTRK fusions are the focus of new therapeutic options, but clonal and subclonal lesions are notoriously difficult to detect. 

Jun
19

This webinar will discuss cell-free DNA prenatal screening in the era of genome-wide sequencing and factors influencing the clinical utility of expanded noninvasive prenatal testing (NIPT) menus.